BE810310A - 4-phenylpiperidines et leur preparation - Google Patents

4-phenylpiperidines et leur preparation

Info

Publication number
BE810310A
BE810310A BE140304A BE140304A BE810310A BE 810310 A BE810310 A BE 810310A BE 140304 A BE140304 A BE 140304A BE 140304 A BE140304 A BE 140304A BE 810310 A BE810310 A BE 810310A
Authority
BE
Belgium
Prior art keywords
phenylpiperidines
preparation
Prior art date
Application number
BE140304A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE810310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BE810310A publication Critical patent/BE810310A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE140304A 1973-01-30 1974-01-29 4-phenylpiperidines et leur preparation BE810310A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (1)

Publication Number Publication Date
BE810310A true BE810310A (fr) 1974-05-16

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
BE140304A BE810310A (fr) 1973-01-30 1974-01-29 4-phenylpiperidines et leur preparation

Country Status (20)

Country Link
US (2) US3912743A (fr)
JP (2) JPS5946216B2 (fr)
AT (1) AT333759B (fr)
BE (1) BE810310A (fr)
CA (1) CA1038390A (fr)
CH (1) CH592059A5 (fr)
DE (1) DE2404113C2 (fr)
DK (1) DK149843C (fr)
ES (2) ES422734A1 (fr)
FI (1) FI57932C (fr)
FR (1) FR2215233B1 (fr)
GB (1) GB1422263A (fr)
HK (1) HK13081A (fr)
IE (1) IE38801B1 (fr)
IT (1) IT1054157B (fr)
LU (2) LU69264A1 (fr)
NL (2) NL179187C (fr)
NO (1) NO144568C (fr)
PH (1) PH10383A (fr)
SE (1) SE401827B (fr)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (da) * 1983-03-07 1987-02-02 Ferrosan As Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (fr) * 1984-12-13 1987-05-27 Beecham Group Plc Dérivés de la pipéridine à activité gastro-intestinale
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (fr) * 1985-08-10 1991-07-10 Beecham Group Plc Procédé de préparation d'aryl-pipéridine-carbinols
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
WO1992009281A2 (fr) * 1990-11-24 1992-06-11 Beecham Group Plc Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (fr) * 1993-08-19 1995-02-22 Novo Nordisk A/S Dérivés de pipéridine, leur préparation et leur utilisation dans le traitement des maladies neurodégénératives
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
JPH11505229A (ja) * 1995-05-17 1999-05-18 ノボ ノルディスク アクティーゼルスカブ ４−アリール−ピペリジン誘導体を製造する方法
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (fr) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentialisation de la sérotonine
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (fr) * 1996-05-30 1997-11-30 Shu-Zhong Wang Methode de preparation de chlorhydrate de paroxetine amorphe
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
ES2331937T3 (es) 1996-06-13 2010-01-20 Sumitomo Chemical Company, Limited Derivados de piperidina como intermediarios para la preparacion de paroxetina y procedimiento de preparacion de los mismos.
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
DE69840909D1 (de) * 1997-04-07 2009-07-30 Univ Georgetown Analoge von kokain
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
WO1998053824A1 (fr) 1997-05-29 1998-12-03 Smithkline Beecham Corporation Nouveau procede
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
KR100543614B1 (ko) 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
CA2212451C (fr) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Preparation stereoselective et utile de 4-arylpiperidines substituees en position 3
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
SK13622000A3 (sk) * 1998-03-16 2001-03-12 Smithkline Beecham Plc Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
TR200002939T2 (tr) * 1998-04-09 2001-02-21 Smithkline Beecham Plc Paroksetin maleat
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
EP0969002B1 (fr) 1998-06-29 2003-08-27 SUMIKA FINE CHEMICALS Co., Ltd. L-Tartrate de trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidines et leur procédé de préparation
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
DE69907467T2 (de) * 1998-08-07 2004-03-11 Smithkline Beecham Plc, Brentford Verfahren zur herstellung von einer nicht-kristallinen wasswerfreien form von paroxetin hydrochlorid
CA2346537A1 (fr) 1998-10-07 2000-04-13 Gian Luca Araldi Heterocycles monomeres et dimeres et leurs utilisations therapeutiques
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
EP1408039A3 (fr) * 1998-11-30 2004-05-12 Smithkline Beecham Plc Solvates mixtes de propan-2-ol et de paroxetine
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
AU2200400A (en) * 1998-12-22 2000-07-12 Pentech Pharmaceuticals, Inc. Process for preparing arylpiperidine carbinol intermediates and derivatives
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
ATE248165T1 (de) * 1999-07-01 2003-09-15 Italfarmaco Spa Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
WO2001029002A1 (fr) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Preparation d'esters de 4-(fluorophenyl)piperidine
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
AU2000246280A1 (en) 2000-05-12 2001-11-20 Synthon B.V. Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
US20040087795A1 (en) * 2000-07-17 2004-05-06 Borrett Gary Thomas Novel processes for the preparation of 4-phenylpiperidine derivatives
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
WO2002028834A1 (fr) * 2000-10-06 2002-04-11 Smithkline Beecham P.L.C. Procede de preparation de carbonols d'aryl-piperidine et produits intermediaires de ces derniers
WO2002032870A1 (fr) * 2000-10-20 2002-04-25 Smithkline Beecham P.L.C. Procede de preparation de composes de -4-aryle piperidine substitue en position 3
MXPA03006057A (es) * 2001-01-04 2004-01-26 Ferrer Intertacional S A Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
AU2002232017A1 (en) * 2001-02-24 2002-09-12 Spurcourt Limited Process of preparing paroxetine and intermediates for use therein
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1406624A4 (fr) * 2001-06-13 2005-03-30 Teva Pharma Procede de preparation de paroxetine sensiblement exempte d'impuretes alcoxy
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
HUP0401895A2 (hu) * 2001-10-22 2004-12-28 Synthon B.V. Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2471715A1 (fr) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. Formulation pharmaceutique stable d'hydrochlorure de paroxetine anhydre et procede de preparation
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
US7560562B2 (en) * 2002-11-01 2009-07-14 Neurosearch A/S Piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004043921A1 (fr) * 2002-11-11 2004-05-27 Natco Pharma Limited Nouveau procede de preparation de 4-aryl-3-hydroxymethyl-1-methylpiperidines
EP1658283A2 (fr) 2003-05-30 2006-05-24 Ranbaxy Laboratories, Ltd. Derives substitues du pyrrole et leur utilisation comme inhibiteurs de hmg-co
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EA200801812A1 (ru) * 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2547283C (fr) * 2003-11-26 2010-11-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
EP2343073A3 (fr) 2003-12-11 2011-10-12 Sepracor Inc. Combinaison de sédatif et modulateur neurotransmetteur et procédés d'amélioration de la qualité du sommeil et de traitement de la dépression
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (fr) * 2004-08-18 2006-02-23 Synthon B.V. Compositions liquides de paroxetine
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
US9597314B2 (en) 2005-03-22 2017-03-21 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2603900A1 (fr) * 2005-04-22 2006-11-02 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
PE20070093A1 (es) * 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
MX2007012883A (es) 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
EP1871358A1 (fr) 2005-04-22 2008-01-02 Wyeth Derives d'alcanamine de benzofuranyle et leurs utilisations comme agonistes 5-ht2c
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
WO2007008758A2 (fr) * 2005-07-08 2007-01-18 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
US8048874B2 (en) 2005-07-19 2011-11-01 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2625153A1 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
EP1948646A2 (fr) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
WO2007112014A2 (fr) * 2006-03-24 2007-10-04 Wyeth Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008034032A2 (fr) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Modulateurs du récepteur cannabinoïde de type bêta-lactame
EP2066355A2 (fr) * 2006-09-19 2009-06-10 Braincells, Inc. Combinaison comprenant un agent ppar et un deuxième agent neurogène pour le traitement d'une maladie du système nerveux central, pour augmenter la différentiation neuronale et pour augmenter la neurogenèse
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008086483A2 (fr) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation de la neurogenèse en utilisant du modafinil
WO2009014910A2 (fr) 2007-07-19 2009-01-29 Metabolex, Inc. Agonistes de recepteurs heterocycliques a liaison n utilises dans le traitement du diabete et des troubles metaboliques
WO2009035652A1 (fr) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthèse de benzo[d][1,3]dioxoles et de catéchols deutériés, ainsi que de leurs dérivés
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010008739A2 (fr) * 2008-06-20 2010-01-21 Metabolex, Inc. Agonistes des récepteurs gpr119 aryles et utilisations associées
AR074350A1 (es) 2008-11-14 2011-01-12 Theravance Inc Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
EP2523945A1 (fr) 2010-01-11 2012-11-21 Theravance, Inc. Composés de type 1-(2-phénoxyméthylphényl)pipérazine comme inhibiteurs du recaptage de la sérotonine et de la norépinéphrine
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
EP3351104B1 (fr) 2010-07-01 2020-12-09 Azevan Pharmaceuticals, Inc. Composés pour le traitement du trouble explosif intermittent
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
CN104039777B (zh) 2012-01-31 2016-03-02 卫材R&D管理有限公司 帕罗西汀衍生物
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
CA3075759A1 (fr) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions et procedes pour le traitement d'une lesion cerebrale
CA3145388A1 (fr) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Regimes de traitement non sedatifs a base de dexmedetomidine
WO2023102477A1 (fr) * 2021-12-02 2023-06-08 The Johns Hopkins University Inhibiteurs à restriction périphérique et luminale du transporteur de la sérotonine en tant que traitements pour des troubles de la motilité gastro-intestinale et de l'axe intestin-cerveau
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
CA1038390A (fr) 1978-09-12
NL7401189A (fr) 1974-08-01
HK13081A (en) 1981-04-10
NO144568B (no) 1981-06-15
NL930003I2 (nl) 1994-03-01
FR2215233B1 (fr) 1977-01-28
ATA69674A (de) 1976-04-15
JPS5948826B2 (ja) 1984-11-29
GB1422263A (en) 1976-01-21
DE2404113C2 (de) 1985-07-11
PH10383A (en) 1977-03-02
NO144568C (no) 1981-09-23
CH592059A5 (fr) 1977-10-14
ES8707224A3 (es) 1987-07-16
JPS5946216B2 (ja) 1984-11-10
IE38801L (en) 1974-07-30
US4007196A (en) 1977-02-08
FR2215233A1 (fr) 1974-08-23
IE38801B1 (en) 1978-06-07
JPS49101385A (fr) 1974-09-25
NL179187B (nl) 1986-03-03
DK149843B (da) 1986-10-13
SE401827B (sv) 1978-05-29
LU69264A1 (fr) 1974-04-10
IT1054157B (it) 1981-11-10
DE2404113A1 (de) 1974-08-08
ES422734A1 (es) 1976-04-01
DK149843C (da) 1987-06-15
JPS58174363A (ja) 1983-10-13
FI57932B (fi) 1980-07-31
LU88398I2 (fr) 1994-05-04
US3912743A (en) 1975-10-14
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
AT333759B (de) 1976-12-10
ES556013A0 (es) 1987-07-16
FI57932C (fi) 1980-11-10

Similar Documents

Publication Publication Date Title
BE810310A (fr) 4-phenylpiperidines et leur preparation
BE813356A (fr) Penicillines et leur preparation
BE799379R (fr) Amino-alcools et leur preparation.
BE820163A (fr) Triazolopyridazines et leur preparation
BE795907A (fr) 2-amino-4-arylthiazoles 5-substitues et leur preparation
BE800781A (fr) Oxathiazinones et leur preparation
BE797101A (fr) Chlorothiazoles et leur preparation
BE833586A (fr) Aminobenzazocines et leur preparation
BE832860A (fr) Benzo-isoquinoleine-diones et leur preparation
BE810841A (fr) Perfluoro-amino-ethers tertiaires et leur preparation
BE819627A (fr) Pigments azomethiniques et leur preparation
BE818234A (fr) Polyimides et leur preparation
BE792906A (fr) Aryl-cetones et leur preparation
BE783272A (fr) Triazolobenzodiazepines et leur preparation
BE815498A (fr) Derives de triazolo-isoquinoleine et leur preparation
BE825982A (fr) Triazoloquinazolines et leur preparation
BE811913A (fr) Pigments bis-azoiques et leur preparation
BE785375A (fr) Thiolincosaminides et leur preparation
BE811105A (fr) Colorants mono-azo-methiniques et leur preparation
BE820256A (fr) Nouvelles phenoxyalkylamines et leur preparation
BE815745A (fr) Aminopropanols et leur preparation
BE816693A (fr) Pigments bis-azoiques et leur preparation
BE816809A (fr) Pigments bis-azoiques et leur preparation
BE823585A (fr) Pigments bis-azoiques et leur preparation
BE795881A (fr) Tribromopyrazoles et leur preparation

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 093C0029

CCPV Grant of a supplementary protection certificate

Free format text: 093C0029, EXPIRES 19990129

RE20 Patent expired

Owner name: NOVO NORDISK A/S

Effective date: 19940129